Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

911.00INR
28 Feb 2015
Change (% chg)

-- (--)
Prev Close
Rs911.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
172,481
52-wk High
Rs965.90
52-wk Low
Rs552.50

SUN.BO

Chart for SUN.BO

About

Sun Pharmaceutical Industries Ltd. (Sun) is an international pharmaceutical company. The Company manufactures and markets a variety of pharmaceutical formulations as branded generics, as well as generics in the United States, India and several other global markets. It operates through four segments, including US Generics, Indian... (more)

Overall

Beta: 0.62
Market Cap(Mil.): Rs1,820,346.00
Shares Outstanding(Mil.): 2,071.16
Dividend: 1.50
Yield (%): 0.17

Financials

  SUN.BO Industry Sector
P/E (TTM): 30.70 38.87 40.17
EPS (TTM): 28.63 -- --
ROI: -- 16.97 16.27
ROE: -- 17.50 17.24
Search Stocks

CORRECTED-BUZZ-India's Suzlon rises to daily upper limit on turnaround hopes

** Suzlon Energy shares jump as much as 20 pct to daily upper limit

18 Feb 2015

Sun Pharma third-quarter profit falls

MUMBAI - Sun Pharmaceutical Industries Ltd, India's largest drugmaker, said on Saturday third-quarter net profit fell unexpectedly due to a decline in sales in the United States and costs from resolving regulatory issues at a manufacturing plant.

14 Feb 2015

BUZZ-India's Suzlon gains on talk of investment by Sun Pharma founder

** Traders cite persistent speculation that billionaire and Sun Pharmaceutical Industries Ltd's founder Dilip Shanghvi is looking to invest in the company in a personal capacity

12 Feb 2015

Deals of the day- Mergers and acquisitions

Jan 30 - The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Friday:

31 Jan 2015

Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

WASHINGTON - India's Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the U.S. Federal Trade Commission said on Friday.

31 Jan 2015

Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

WASHINGTON - India's Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the U.S. Federal Trade Commission said on Friday.

31 Jan 2015

UPDATE 1-Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

WASHINGTON, Jan 30 - India's Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the U.S. Federal Trade Commission said on Friday.

31 Jan 2015

Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

WASHINGTON, Jan 30 - Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sells its interest in a generic anti-bacterial medicine, the Federal Trade Commission said on Friday.

31 Jan 2015

BUZZ-JPMorgan upgrades India's Sun Pharma to "overweight"

** JPMorgan upgrades Sun Pharmaceutical Industries Ltd to "overweight" from "neutral"

06 Jan 2015

REFILE-BUZZ-Indian shares to be governed by global events in near term - Credit Suisse

(Corrects spelling of Thomson Reuters Datastream in second bullet point) ** Since expansion in P/E multiples drove 3/5th of India's market performance in 2014, questions arise over whether rally is sustainable this year - Credit Suisse ** MSCI India index 1-yr forward P/E expands to 17.2 vs 14.6 at the start of 2014 - Thomson Reuters Datastream ** India's NSE index rose 31.4 pct in 2014, making it best performing market in Asia after China ** Global linkages to drive market, ap

05 Jan 2015

Earnings vs. Estimates

Search Stocks